Application of interleukin 12 to antitumor cytokine and gene therapy

Cancer Chemotherapy and Pharmacology, Supplement

Volumn 38, Issue , 1996, Pages

  Nishimura, Takashi ^a   Watanabe, Kazuhito ^a   Yahata, Takashi ^a   Ushaku, Lee ^a   Ando, Kiyoshi ^a   Kimura, Minoru ^a   Saiki, Ikuo ^b   Uede, Toshimitsu ^c   Habu, Sonoko ^a  

^a TOKAI UNIVERSITY   (Japan)

^b UNIVERSITY OF TOYAMA   (Japan)

^c HOKKAIDO UNIVERSITY   (Japan)

Author keywords

Cytokine therapy; Gene therapy; IL 12; Tumor

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 2; METHYLNITROSOUREA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; B CELL LYMPHOMA; CANCER IMMUNOTHERAPY; CONFERENCE PAPER; CONTROLLED STUDY; GENE THERAPY; INTRAPERITONEAL DRUG ADMINISTRATION; MELANOMA B16; MOUSE; NATURAL KILLER CELL; NONHUMAN; ONCOGENE H RAS; PRIORITY JOURNAL; TRANSGENIC MOUSE;

EID: 0029791416     PISSN: 09439404     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800051033     Document Type: Conference Paper

References (23)

1. Ando K, Saitoh A, Hino O, Takahashi R, Kimura M, Katsuki M (1992) Chemically induced forestomach papillomas in transgeneic mice cany mutant human c-Ha-ras transgene. Cancer Res 52: 978
2. Brunda MJ, Luistro L, Warrier RR, Wright RB, Hubbard BR, Murphy M, Wolf SF, Gately MK (1993) Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med 178: 223
3. Fearon ER, Pardoll DM, Itaya T, Golombek P, Levitsky HI, Simins JW, Karasuyama H, Vogelstein B, Frost P (1990) Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 60: 397
4. Hamaoka T, Fujiwara H (1987) Phenotypically and functionally distinct T-cell subsets in anti-tumor responses. Immunol Today 8: 267
5. Hashimoto W, Takeda K, Anzai R, Ogasawara K, Sakihara H, Sugiura K, Seki S, Kumagai K (1995) Cytotoxic NK1.1 Ag+ alpha beta T-cells with intermediate TCR induced in the liver of mice by IL-12. J Immunol 154: 4333
6. Karasuyama H, Melcher F (1988) Establishment of mouse cell lines which constitutively secrete large quantities of interleukin 2, 3, 4 or 5, using modified cDNA expression vector. Eur J Immunol 18: 97
7. + helper/killer T-cell phenomenon: selective induction of Th1 type of helper/killer T-cells and application to tumor immunotherapy. J Immunol 154: 1777
8. + cytotoxic T lymphocytes from tumor-infiltrating lymphocytes. Jpn J Cancer Res 86: 135
9. Lee U, Santa K, Habu S, Nishimura T (1996) Murine asia-loGM1+CD8+ T-cells as novel interleukin-12-responding killer T-cell precursors. Jpn J Cancer Res (in press)
10. Murphy EE, Terres G, Macatonia SE, Hsieh C-S, Mattson J, Lanier L, Wysocka M, Trinchieri G, Murphy K, O'Garra A (1994) B7 and interleukin 12 cooperate for proliferation and interferon γ production by mouse T helper clones that are unresponsive to B7 costimulation. J Exp Med 180: 223
11. Nakamura Y, Wakimoto H, Abe J, Kanegae Y, Saito I, Aoyagi M, Hirakawa K, Hamada H (1994) Adoptive immunotherapy with murine tumor-specific T lymphocytes engineered to secrete interleukin 2. Cancer Res 54: 5757
12. Nastala CL, Edington HD, McKinney TG, Tahara H, Nalesnik MA, Brunda MJ, Gately MK, Wolf SF, Schreiber RD, Storkus WJ, Lotze MT (1994) Recombinant IL-12 administration induces tumor regression in association with IFN-γ production. J Immunol 153: 1697
13. Nishimura T, Togashi Y, Goto M, Yagi H, Uchiyama Y, Hashimoto Y (1986) Augmentation of the therapeutic efficacy of , adoptive tumor immunotherapy by in vivo administration of slowly released recombinant interleukin 2. Cancer Immunol Immunother 21: 12
14. Nishimura T, Burakoff SJ, Herrmann SH (1987) Protein kinase C required for cytotoxic T lymphocyte triggering. J Immunol 130: 2888
15. Nishimura T, Uchiyama Y, Hashimoto Y (1988) In vivo generation of lymphokine-activated killer cells by sensitization with interleukin 2-producing syngeneic T-lymphoma cells. Cell Immunol 112: 220
16. + helper/killer T-cells induced by anti-CD3 monoclonal antibody plus recombinant IL-2: an efficient strategy for adoptive tumor immunotherapy. J Immunol 148: 285
17. Nishimura T, Nakamura Y, Tsukamoto H, Takeuchi Y, Tokuda Y, Iwasawa M, Yamamoto T, Masuko T, Hashimoto Y, Habu S (1992) Human c-erbB-2 proto-oncogene product as a target for bispecific-antibody-directed adoptive tumor immunotherapy. Int J Cancer 50: 800
18. Noguchi Y, Richards EC, Chen Y-T, Old LJ (1995) Influence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma. Proc Natl Acad Sci USA 92: 2219
19. Saito I, Oya Y, Yamamoto K, Yuasa T, Shimojo H (1985) Construction of nondefective adenovirus type 5 bearing a 2.8-kilobase hepatitis B virus DNA near the right end of its genome. J Virol 54: 711
20. Tada T, Ozeki S, Utsumi K, Takiuchi H, Muramatsu M, Li X-F, Shimizu J, Fujiwara H, Hamaoka T (1991) Transforming growth factor-β-induced inhibition of T-cell function: susceptibility difference in T-cells of various phenotypes and functions and its relevance to immunosuppression in the tumor-bearing state. J Immunol 146: 1077
21. Tahara H, Zer HJ III, Storkus WJ, Pappo I, Watkins SC, Gubler U, Walf SF, Robbins PD, Lotze MT (1994) Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res 54: 182
22. Trinchieri G (1995) Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. Blood 84: 4008
23. Van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plean E, Van Den Eynde B, Knuth A, Boon T (1991) A gene coding an antigen recognized by cytotoxic T lymphocytes on a human melanoma. Science 254: 1643